Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PTPN11
REST API REST API
Homo sapiens
PTPN11 is differentially expressed in 350 experiments: 156 organism parts: bone marrow, liver, ... (154 more);, 254 disease states: normal, cervical carcinoma, ... (252 more);, 104 cell types 421 cell lines 45 compound treatments and 85 other conditions.
Synonyms SHP-2, NS1, BPTP3, SHP2, PTP2C, SH-PTP2
Orthologs ENSCING00000003686 (Ciona intestinalis)   ENSCING00000016529 (Ciona intestinalis)   Ptpn11 (Mus musculus)   Ptpn11 (Rattus norvegicus)   PTPN11 (Bos taurus)   ptpn11a (Danio rerio)   csw (Drosophila melanogaster)   PTPN11 (Gallus gallus)   PTPN11 (Xenopus laevis)   PTPN11 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term regulation of multicellular organism growth, cytosol, phosphatase activity, DNA damage checkpoint, protein binding, cytokine-mediated signaling pathway, cytoplasm, epidermal growth factor receptor signaling pathway, protein complex, dephosphorylation, hormone-mediated signaling pathway, insulin receptor binding, phosphoprotein phosphatase activity, insulin receptor signaling pathway, insulin receptor substrate binding, blood coagulation, protein domain specific binding, glucose homeostasis, fibroblast growth factor receptor signaling pathway, organ growth, activation of MAPK activity, soluble fraction, protein tyrosine phosphatase activity, axon guidance, triglyceride metabolic process, lipid metabolic process, axonogenesis, hydrolase activity, non-membrane spanning protein tyrosine phosphatase activity, positive regulation of hormone secretion, regulation of cell adhesion mediated by integrin, mitochondrion, regulation of interferon-gamma-mediated signaling pathway, hormone metabolic process, leukocyte migration, regulation of type I interferon-mediated signaling pathway, negative regulation of hormone secretion, peptidyl-tyrosine dephosphorylation, negative regulation of growth hormone secretion, ephrin receptor signaling pathway, negative regulation of insulin secretion, negative regulation of cortisol secretion, regulation of protein export from nucleus, positive regulation of signal transduction, nerve growth factor receptor signaling pathway, peptide hormone receptor binding, phospholipase binding, T cell costimulation, platelet activation, protein dephosphorylation, interferon-gamma-mediated signaling pathway, type I interferon-mediated signaling pathway, multicellular organismal reproductive process, cell junction assembly
InterPro Term SH2, Tyr_Pase_cat, Tyr_Pase_rcpt/non-rcpt, Tyr_Pase_non-rcpt_typ-6/11, Tyr/Dual-specificity_Pase
UniProt Accession Q06124, B3GUD3, B3GUD4
Gene-Disease Assocation LEOPARD SYNDROME 1, METACHONDROMATOSIS, JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML, NOONAN SYNDROME 1; NS1
Search EB-eye ENSG00000179295
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
SKBR3
2
E-MTAB-62, E-MEXP-440
SNU16
2
E-GEOD-15460, E-MTAB-37
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MDA-MB-231
2
E-TABM-420, E-MTAB-62
415 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-21750, ... (50 experiments)

Factor Value U/D Experiments
CD34+
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
testis - germ cell
2
E-AFMX-5, E-TABM-145
fibroblast
1
2
E-GEOD-3920, E-GEOD-26672, E-GEOD-3204
type I helper T cell
1
E-GEOD-3982
secretory cell
1
E-GEOD-3998
98 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-GEOD-12254, ... (78 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MEXP-231, E-MTAB-62, E-MTAB-37, E-GEOD-2514
acute promyelocytic leukemia
3
E-MTAB-62, E-GEOD-995, E-GEOD-1729
cervical carcinoma
1
3
E-MTAB-62, E-MTAB-37, E-MEXP-1331, E-GEOD-5823
bladder carcinoma
2
E-MTAB-37, E-TABM-147
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MTAB-62, E-MEXP-66
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
248 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-MEXP-1958, ... (27 experiments)

Factor Value U/D Experiments
none
3
5
E-GEOD-5824, E-GEOD-412, E-MEXP-1958, E-TABM-782, E-GEOD-995, ... (8 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
keratinocyte growth factor
1
E-GEOD-7216
placebo
1
E-MEXP-1327
cadmium chloride 2.5-hydrate
1
E-GEOD-6907
39 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
102.14
1
1
E-TABM-325
89.02
1
1
E-TABM-325
74.51
1
1
E-TABM-325


Age years
studied in E-TABM-783

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (12 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-860, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-MTAB-69, E-TABM-147, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-1045, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-10315, E-TABM-440, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-MEXP-2069, E-GEOD-1926, ... (44 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-MEXP-2177

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-2487, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

pt
studied in E-GEOD-21653

Qrt pcr ereg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-19330

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Tumor size
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.301 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM